Integra LifeSciences Lowers FY23 Guidance, Sees Revenue Of $1.548B- $1.560B (Prior View $1.602B-$1.62B) Vs. Consensus Of $1.56B; Adjusted EPS Of $3.10 To $3.18 (Prior $3.43-$3.51) Vs. Consensus Of $3.12
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences has lowered its FY23 guidance, with expected revenue of $1.548B-$1.560B, down from the previous estimate of $1.602B-$1.62B. The new revenue forecast is in line with the consensus of $1.56B. The company also revised its adjusted EPS to $3.10-$3.18, down from $3.43-$3.51, slightly below the consensus of $3.12.
July 27, 2023 | 4:37 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra LifeSciences has lowered its FY23 guidance, which could potentially impact its stock price negatively in the short term.
Integra LifeSciences has lowered its FY23 guidance, which indicates that the company expects lower revenue and earnings than previously estimated. This could lead to a negative sentiment among investors, potentially causing a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100